Stifel Initiates Coverage On Inozyme Pharma with Buy Rating, Announces Price Target of $16
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Dae Gon Ha has initiated coverage on Inozyme Pharma (NASDAQ:INZY) with a Buy rating and set a price target of $16.
September 12, 2024 | 10:46 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel has initiated coverage on Inozyme Pharma with a Buy rating and a price target of $16, indicating a positive outlook for the stock.
The initiation of coverage with a Buy rating and a specific price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100